252 related articles for article (PubMed ID: 35510808)
21. [Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents].
Morita M
Yakugaku Zasshi; 2007 Jul; 127(7):1059-64. PubMed ID: 17603264
[TBL] [Abstract][Full Text] [Related]
22. Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy.
Asheuer M; Bieche I; Laurendeau I; Moser A; Hainque B; Vidaud M; Aubourg P
Hum Mol Genet; 2005 May; 14(10):1293-303. PubMed ID: 15800013
[TBL] [Abstract][Full Text] [Related]
23. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
Baarine M; Beeson C; Singh A; Singh I
J Neurochem; 2015 May; 133(3):380-96. PubMed ID: 25393703
[TBL] [Abstract][Full Text] [Related]
24. Abcd1 deficiency accelerates cuprizone-induced oligodendrocyte loss and axonopathy in a demyelinating mouse model of X-linked adrenoleukodystrophy.
Martinović K; Bauer J; Kunze M; Berger J; Forss-Petter S
Acta Neuropathol Commun; 2023 Jun; 11(1):98. PubMed ID: 37331971
[TBL] [Abstract][Full Text] [Related]
25. ABC subfamily D proteins and very long chain fatty acid metabolism as novel targets in adrenoleukodystrophy.
Morita M; Shimozawa N; Kashiwayama Y; Suzuki Y; Imanaka T
Curr Drug Targets; 2011 May; 12(5):694-706. PubMed ID: 21039332
[TBL] [Abstract][Full Text] [Related]
26. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy.
McGuinness MC; Lu JF; Zhang HP; Dong GX; Heinzer AK; Watkins PA; Powers J; Smith KD
Mol Cell Biol; 2003 Jan; 23(2):744-53. PubMed ID: 12509471
[TBL] [Abstract][Full Text] [Related]
27. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy.
Fourcade S; López-Erauskin J; Galino J; Duval C; Naudi A; Jove M; Kemp S; Villarroya F; Ferrer I; Pamplona R; Portero-Otin M; Pujol A
Hum Mol Genet; 2008 Jun; 17(12):1762-73. PubMed ID: 18344354
[TBL] [Abstract][Full Text] [Related]
28. Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy.
Weinhofer I; Forss-Petter S; Zigman M; Berger J
Hum Mol Genet; 2002 Oct; 11(22):2701-8. PubMed ID: 12374760
[TBL] [Abstract][Full Text] [Related]
29. Evidence of oxidative stress in very long chain fatty acid--treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins.
Baarine M; Andréoletti P; Athias A; Nury T; Zarrouk A; Ragot K; Vejux A; Riedinger JM; Kattan Z; Bessede G; Trompier D; Savary S; Cherkaoui-Malki M; Lizard G
Neuroscience; 2012 Jun; 213():1-18. PubMed ID: 22521832
[TBL] [Abstract][Full Text] [Related]
30. Dendrimer-N-acetyl-L-cysteine modulates monophagocytic response in adrenoleukodystrophy.
Turk BR; Nemeth CL; Marx JS; Tiffany C; Jones R; Theisen B; Kambhampati S; Ramireddy R; Singh S; Rosen M; Kaufman ML; Murray CF; Watkins PA; Kannan S; Kannan R; Fatemi A
Ann Neurol; 2018 Sep; 84(3):452-462. PubMed ID: 30069915
[TBL] [Abstract][Full Text] [Related]
31. Case report of dysregulation of primary bile acid synthesis in a family with X-linked adrenoleukodystrophy.
Płatek T; Orso E; Zapała B; Polus A; Kieć-Wilk B; Piwowar M; Chojnacka M; Ciałowicz U; Malczewska-Malec M; Schmitz G; Solnica B; Dembińska-Kieć A
Medicine (Baltimore); 2018 Dec; 97(49):e13353. PubMed ID: 30544401
[TBL] [Abstract][Full Text] [Related]
32. A novel ABCD1 gene mutation causes adrenomyeloneuropathy presenting with spastic paraplegia: A case report.
Liu J; Wang X; Huang D; Qi Y; Xu L; Shao Y
Medicine (Baltimore); 2024 Apr; 103(16):e37874. PubMed ID: 38640304
[TBL] [Abstract][Full Text] [Related]
33. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy.
Ofman R; Dijkstra IM; van Roermund CW; Burger N; Turkenburg M; van Cruchten A; van Engen CE; Wanders RJ; Kemp S
EMBO Mol Med; 2010 Mar; 2(3):90-7. PubMed ID: 20166112
[TBL] [Abstract][Full Text] [Related]
34. Drug discovery for X-linked adrenoleukodystrophy: An unbiased screen for compounds that lower very long-chain fatty acids.
Moser AB; Liu Y; Shi X; Schrifl U; Hiebler S; Fatemi A; Braverman NE; Steinberg SJ; Watkins PA
J Cell Biochem; 2021 Oct; 122(10):1337-1349. PubMed ID: 34056752
[TBL] [Abstract][Full Text] [Related]
35. Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.
Singh I; Pujol A
Brain Pathol; 2010 Jul; 20(4):838-44. PubMed ID: 20626745
[TBL] [Abstract][Full Text] [Related]
36. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects.
Kemp S; Berger J; Aubourg P
Biochim Biophys Acta; 2012 Sep; 1822(9):1465-74. PubMed ID: 22483867
[TBL] [Abstract][Full Text] [Related]
37. Very-long-chain fatty acid metabolism in adrenoleukodystrophy protein-deficient mice.
Yamada T; Shinnoh N; Kondo A; Uchiyama A; Shimozawa N; Kira J; Kobayashi T
Cell Biochem Biophys; 2000; 32 Spring():239-46. PubMed ID: 11330052
[TBL] [Abstract][Full Text] [Related]
38. ABCD1 and X-linked adrenoleukodystrophy: A disease with a markedly variable phenotype showing conserved neurobiology in animal models.
Manor J; Chung H; Bhagwat PK; Wangler MF
J Neurosci Res; 2021 Dec; 99(12):3170-3181. PubMed ID: 34716609
[TBL] [Abstract][Full Text] [Related]
39. Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy.
Gong Y; Mu D; Prabhakar S; Moser A; Musolino P; Ren J; Breakefield XO; Maguire CA; Eichler FS
Mol Ther; 2015 May; 23(5):824-834. PubMed ID: 25592337
[TBL] [Abstract][Full Text] [Related]
40. Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy.
Raas Q; van de Beek MC; Forss-Petter S; Dijkstra IM; Deschiffart A; Freshner BC; Stevenson TJ; Jaspers YR; Nagtzaam L; Wanders RJ; van Weeghel M; Engelen-Lee JY; Engelen M; Eichler F; Berger J; Bonkowsky JL; Kemp S
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33690217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
